- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01821547
New Methods to Measure the Immune Response to Hepatitis B Vaccine
Hepatitis B Immunisation: A Two-part Study Investigating Antigen Specific B Cell Receptors
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Oxfordshire
-
Oxford, Oxfordshire, United Kingdom, OX3 7LE
- Centre for Clinical Vaccinology & Tropical Medicine (CCVTM)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All participants for both parts 1 and 2 must meet the following conditions in order to be enrolled:
- Participant is willing and able to give informed consent for participation in the study
- Healthy Male or Female, aged 18 - 60 years
- No allergies to the vaccine or its excipients
Participants enrolling in Part 1 must also meet the following conditions:
- Participant has previously received a primary immunisation course of HepB vaccine (3 primary doses). The 4th booster dose recommended after 12 months is not a requirement. There are a variety of possible recommended schedules, and any may have been used as long as the final vaccine (or booster vaccine) was given at least 12 months prior to the participant enrolling in the study.
- Participant is willing to allow their General Practitioner to be notified, if appropriate, of participation in the study
Participants enrolling in Part 2 must also meet the following conditions Participant receiving HBvaxPro® (the usual vaccine given within the Occupational Health Department).
Exclusion Criteria:
The participant may not enter either study if ANY of the following apply:
Have any known or suspected impairment or alteration of immune function, resulting from, for example:
- Congenital or acquired immunodeficiency (including IgA deficiency)
- Human Immunodeficiency Virus infection or symptoms/signs suggestive of an HIV-associated condition
- Autoimmune disease
- Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 12 months or long-term systemic corticosteroid therapy.
- Chronic illness that could interfere with immunological function or donation of the required volumes of blood (e.g. cardiac or renal disease, diabetes, or auto-immune disorders).
- Receipt of a HepB booster vaccine within the past 12 months.
- Prior history of anaphylactic reaction to a previous dose of a Hepatitis B containing vaccine or known hypersensitivity to any vaccine component;
- Receipt of blood, blood products, or plasma derivatives within the past 3 months.
- Total blood donation greater than 50 ml within the past 3 months.
- Thrombocytopenia or any bleeding disorder.
- Pregnancy as confirmed by a positive pregnancy test, or currently breastfeeding.
- Receipt of a live vaccine within 4 weeks prior to vaccination or a killed vaccine within 7 days prior to vaccination.
- Plan to receive any vaccine other than the study vaccine within 4 weeks following vaccination.
- Enrolled in another study, which, in the opinion of the investigator, could compromise the integrity of either study being conducted.
- A member of staff on the delegation log
- According to the TOPS database, have recently taken part in a significant number of other studies, which, in the opinion of the investigator, warrant exclusion from further studies.
- Participant is a known non-responder to the HepB vaccine
- Have any condition, which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
- Unable to understand English, or what will be required from them during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 2- To assess B cell VH/L gene segment usage by HepB specific B cells during and following administration of a three dose course of HepB vaccine given at 0,1, 2 or 0, 1, 6 months.
Time Frame: 0 and 7 days after the second immunisation, and 0, 7 and 40 days after the third immunisation
|
HepB specific cells will be isolated using magnetic-activated cell sorting, and fluorescence-activated cell sorting.
VH/L gene segments will be amplified by PCR, and DNA prepared for sequencing.
Bioinformatic approaches will then be used to create frequency tables of the different V, D and J exons that comprise these gene segments.
|
0 and 7 days after the second immunisation, and 0, 7 and 40 days after the third immunisation
|
Part 1- To validate B cell assays and assess the kinetics of HepB specific B cell subsets following administration of a booster dose of HepB vaccine given to previously immunised healthy adults.
Time Frame: 0, 7, 14, 21 and 28 days after immunisation
|
HepB specific B cell subsets will be identified using both ELISPOT and flow cytometry.
|
0, 7, 14, 21 and 28 days after immunisation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 • To measure HepB surface antigen-specific antibody concentration following administration of a booster dose of HepB vaccine given to previously immunised healthy adults
Time Frame: 0 and 28 days after immunisation
|
Antibody concentrations will be determined from blood plasma using an ELISA
|
0 and 28 days after immunisation
|
Part 1 • To assess B-cell receptor VH/L gene sequences used in HepB specific and non-antigen specific B-cells prior to and following administration of a booster dose of HepB vaccine given to previously immunised healthy adults
Time Frame: 0, 7, 14, 21 and 28 days after immunisation
|
VH/L gene segments will be amplified by PCR, and DNA prepared for sequencing.
Bioinformatic approaches will then be used to create frequency tables of the different V, D and J exons that comprise these gene segments.
|
0, 7, 14, 21 and 28 days after immunisation
|
Part 1 • Comparison of B cell receptor VH/L gene segment usage as determined by two different next-generation sequencing methods (RNA-sequencing and 454).
Time Frame: 0, 7, 14, 21 and 28 days after immunisation, as required
|
Different sequencing protocols introduce different types of error and bias into the resulting sequence datasets.
VH/L gene segments will sequenced using two different techniques.
Bioinformatic approaches and descriptive analysis will then be used to compare the effects of the two different protocols.
Frequency tables of the different V, D and J exons that comprise these gene segments will be generated, for comparison.
|
0, 7, 14, 21 and 28 days after immunisation, as required
|
Part 1 • Collection of mRNA for subsequent gene expression analysis
Time Frame: 0, 7, 14, 21 and 28 days after immunisation
|
0, 7, 14, 21 and 28 days after immunisation
|
|
Part 2 • To measure HepB specific plasma and memory B cell frequencies during and following administration of a three dose course of HepB vaccine given at 0, 1, 2 or 0, 1, 6 months.
Time Frame: 0 and 7 days after the second immunisation, and 0, 7 and 40 days after the third immunisation
|
HepB specific B cell subsets will be identified using both ELISPOT and flow cytometry.
|
0 and 7 days after the second immunisation, and 0, 7 and 40 days after the third immunisation
|
Part 2 • To measure HepB surface antigen-specific antibody concentration during and following administration of a three dose course of HepB vaccine given at 0,1, 2 or 0, 1, 6 months.
Time Frame: 0 days after the second immunisation, and 0 and 40 days after the third immunisation
|
Antibody concentrations will be determined from blood plasma using an ELISA
|
0 days after the second immunisation, and 0 and 40 days after the third immunisation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dominic Kelly, Oxford Vaccine Group
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OVG 2012/09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Ain Shams UniversityCompleted
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi... and other collaboratorsRecruitingChronic Hepatitis b | Hepatitis B ReactivationTaiwan
-
Mahidol UniversityUnknownChronic Hepatitis B, HBsAg, Hepatitis B VaccineThailand
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bUnited States
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unknown
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingChronic Hepatitis b | Cirrhosis Due to Hepatitis BChina
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
Clinical Trials on Hepatitis B vaccine
-
PT Bio FarmaRS Umum Pusat Sanglah, DenpasarNot yet recruitingVaccine Adverse Reaction | Vaccine Reaction
-
Jiangsu Province Centers for Disease Control and...CompletedHepadnaviridae Infections | DNA Virus Infections | Virus DiseaseChina
-
Merck Sharp & Dohme LLCCompleted
-
Jiangsu Province Centers for Disease Control and...Shenzhen Kangtai Biological Products Co., LTDCompleted
-
PT Bio FarmaCompleted
-
Tel-Aviv Sourasky Medical CenterUnknownHepatitis B | Chronic Kidney DiseaseIsrael
-
National Taiwan University HospitalNational Science Council, TaiwanCompleted
-
Arto PalmuGlaxoSmithKlineCompletedPneumococcal InfectionsFinland
-
Peking UniversityShenzhen Kangtai Biological Products Co., LTD; Guangxi Center for Disease Control... and other collaboratorsCompleted
-
GlaxoSmithKlineCompleted